Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 9Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Colorectal Neoplasms 3Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcopenia 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myositis 1Metastatic Colorectal Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Hyperthermia 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Heart Diseases 1Glioma 1Eye Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

Imatinib Mesylate 6Doxorubicin 4Mohs Surgery 2saracatinib 1ribociclib 1indolepropanol phosphate 1cixutumumab 1avelumab 1Watchful Waiting 1Sunitinib 1Razoxane 1Radiotherapy, Conformal 1Observation 1MLN 8237 1Immune Checkpoint Inhibitors 1Ifosfamide 1HhAntag691 1Dexrazoxane 1Cyclophosphamide 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Dermatofibrosarcoma × Immune Checkpoint Inhibitors × Clear all
NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

BioAtla, Inc.

Phase 1/2 Completed
245 enrolled
Sarcoma

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡